Zacks Investment Research | Dec 09, 2019 08:32PM ET
Bruker Corporation (NASDAQ:BRKR) launched the Luxendo TruLive3D Imager light-sheet imaging system at the American Society for Cell Biology (ASCB) and European Molecular Biology Organization (“EMBO”). The imager leverages general benefits of single-plane illumination microscopy (SPIM), thus enabling rapid 3D imaging, with negligible light exposure, confocal resolution and excellent contrast in 3D.
With the latest launch, the company aims to strengthen its CALID Group’s ESI-TOF mass spectrometry business on a global scale. Notably, CALID Group is a component of Bruker’s broader segment — Bruker Scientific Instruments (“BSI”).
Few Words on the Product
The Luxendo TruLive3D Imager system maintains user-friendliness and stability of InVi SPIM, and is optimized to allow fast 3D multi-sample imaging of live specimens. Notably, in December 2018, the company launched Luxendo InVi SPIM, the next-generation lattice light-sheet microscope.
Further, Luxendo’s (that Bruker acquired in 2017) latest TruLive3D Dish series is adjusted for light-sheet imaging of cells, 3D cell culture systems, organoids and small animals. The dishes can be easily integrated with the imager, thus maximizing throughput.
Significance of the Launch
Per the company, the Luxendo system will help speed up its experiments, which require using light-sheet imaging. Bruker claims that the latest imager will allow imaging biology in its natural setting, without hampering resolution and imaging speed or causing photo-toxicity.
Industry Prospects
Per a report by Original post
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.